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Abstract  
The existence of diverging discourses in the media and academia on the use of 
prescription medications to improve cognition in healthy individuals, i.e., 
“cognitive enhancement” (CE) creates the need to better understand 
perspectives from stakeholders.  This qualitative focus-group study examined 
perspectives from students, parents and healthcare providers on CE. 
Stakeholders expressed ambivalence regarding CE (i.e., reactions to, definitions 
of, risks, and benefits). They were reluctant to adopt analogies to performance-
enhancing steroids and caffeine though these analogies were useful in 
discussing concepts common to the use of different performance-enhancing 
substances. Media coverage of CE was criticized for lack of scientific rigor, 
ethical clarity, and inadvertent promotion of CE. Ambivalence of stakeholders 
suggests fundamental discomfort with economic and social driving forces of CE. 
Forms of public dialogue that voice the unease and ambivalence of stakeholders 
should be pursued to avoid opting hastily for permissive or restrictive health 
policies for CE.  
Keywords: cognitive enhancement, neuroethics, stakeholder perspective, 
ambivalence, media coverage, focus groups 
Introduction 
The non-medical use of prescription medications to enhance human cognition 
(e.g., concentration, memory, alertness) in healthy individuals is often described 
as “cognitive enhancement” (CE). Studies indicate that methylphenidate (MPH; 
Ritalin), a common treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), 
is being used by university students for non-medical CE purposes in proportions 
ranging from 4% to 11% (Racine and Forlini, 2010; Wilens et al., 2008). 
Combined with growing bioethics debate and media coverage, these studies on 
the non-medical uses of stimulants in university students provide a current and 
well documented example of CE. Proponents of CE in academic bioethics have 
argued that CE, “has much to offer individuals and society” (Greely et al., 2008). 
However, others contend that it is premature to declare CE beneficial given 
existing knowledge gaps (Racine and Forlini, 2009) including limited evidence of 
its safety and its efficacy in enhancing cognition of healthy people (Barch and 
Carter, 2005; Bray et al., 2004; Elliott et al., 1997; Mehta et al., 2000). Further, 
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little attention has been paid to the social context and social factors involved in 
CE practices. A recent study on autonomy and coercion in CE found that 
stakeholders (students, parents, healthcare providers) described enormous 
social pressures to perform, which may in themselves entice use of cognitive 
enhancers (Forlini and Racine, 2009a). Other studies on the attitudes of the 
public and stakeholders found general discomfort with CE in the general public 
and among healthcare providers (Bergstrom and Lynoe, 2008) as well as issues 
with the justice and fairness of using such medications in competitive 
environments (Sabini and Monterosso, 2005). Data on how different stakeholder 
groups view CE on both an ethical and social level is currently sparse but 
indicate that information about the social aspects of CE may be lacking.  
 Examining stakeholder perspectives and public appreciation of the ethical 
and social issues of CE has been suggested to broaden the CE debate and gain 
further insights into social and contextual aspects of CE (Racine and Forlini, 
2009).  Currently, stakeholders face a potentially difficult challenge in sorting 
through the diverging discourses on CE (Forlini and Racine, 2009b). Academic 
bioethics has generated some optimistic accounts of the impact of CE on society 
(Greely et al., 2008) despite an unclear understanding of the perspectives of 
stakeholders and the broader public (Racine and Forlini, 2009) while public 
health discourses are structured around negative labels like “prescription misuse” 
and “prescription abuse”. North American and international media have 
discussed CE as a lifestyle choice referring mainly to the North American context 
and evoked the issue of ‘pharmaceuticalisation’ with regard to CE (Williams et 
al., 2008). Research on the media coverage of modafinil, a sleep cycle regulator 
often associated with CE, has also revealed the use of different frameworks. On 
the one hand, modafinil is constructed as a “wonder drug” (Williams et al., 2008) 
and product that can help control sleep (Coveney et al., 2008). On the other 
hand, media discourses on this topic have voiced cultural and social concerns 
about the regulation of sleep cycles with modafinil especially for enhancement 
purposes (Coveney et al., 2008; Williams et al., 2008). Though the different 
discourses in bioethics, the media, and public health create a rich set of co-
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existing perspectives, they may complicate the stakeholders’ take on the current 
controversy surrounding CE. This study aimed to better understand stakeholder 
reactions to and comprehension of CE for performance enhancement in the 
academic setting in order to address the need to gather more grounded and 
social perspectives on CE.  
Methods1 
Participants 
Three groups of participants were selected, university students 25 and under, 
parents of university students and healthcare providers (HCP). The prevalence of 
the non-medical use of methylphenidate in university student populations has 
been widely studied (Wilens et al., 2008). The age limit on university students 
reflects data showing this practice exists among undergraduate students 
(Babcock and Byrne, 2000; White et al., 2006). Parents of university students 
reflect a generational difference and are directly connected to university 
education. Healthcare providers work closely with medications to treat disease 
making their perspective on the repurposing of MPH for enhancement of interest 
to this study. A HCP was defined as someone having a professional 
responsibility to care for the health of patients (e.g., doctors, nurses, 
pharmacists). No particular expertise with MPH was required.  
Recruitment 
The study and the recruitment strategies were approved by the Research Ethics 
Board (REB) of institutions where the study was conducted. English and French 
recruitment advertisements were posted in common areas of two Montréal area 
universities and affiliated institutions. Advertisements were also featured in 
various Montréal general and student newspapers as well as online classified 
sites. E-mail invitations were sent to major student associations and faculty 
                                                          
1 The data presented in this article is part of a larger study of which the methodology and other non-
overlapping data have been previously published (Forlini and Racine, 2009a). 
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members in healthcare professions. Participants received a fifty dollar 
compensation for participating.  
Focus groups 
Focus groups allowed us to gain insight into stakeholder perspectives as 
opposed to those of individuals. To minimize recruitment bias and encourage 
participation of non-experts, participants remained unexposed to the specific 
subject of the discussion (CE with MPH) until they received the documentation 
package. This package included a print media sample of four articles, a consent 
form and a short questionnaire. The articles were chosen from a systematic print 
media sampling of prior discourse analysis (Racine and Forlini, 2010). To 
maximize the scope of the focus group discussion, articles were selected to 
reflect variability in content (e.g., details about how students obtain pills, effects, 
and testimonials), quality of information, overall coverage of ethical issues, 
length, and country of origin (Laurance, 2003; Morency, 2006; Ross, 2006; 
Zernike, 2005). After reading the articles, participants were asked to fill out an 
anonymous questionnaire collecting demographic data and information about 
prior knowledge of CE with MPH.  
The interview grid for the focus groups was based on the results of prior 
discourse analysis (Racine and Forlini, 2010) and tested with three pilot 
interviews. During the focus groups, participants were first invited to comment 
generally on CE (i.e., propose definitions and react to the frequency and social 
acceptability of CE) and then express their opinions regarding the ethical, social 
and legal issues related to CE (e.g., safety, justice and fairness). They were also 
asked to comment on the potential social and healthcare impacts of CE as well 
as solutions. Finally, participants were asked to give their impression (i.e., 
completeness of information, realism) on the media coverage of MPH for CE 
based on the prompt material. The focus groups were moderated to allow 
spontaneous expression of opinions while ensuring coverage of the topics 
included in the interview grid. 
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Coding 
Each focus group was transcribed verbatim. The transcripts were coded 
systematically according to a previously used coding guide that identified major 
themes and issues from lay, bioethics and public health discourses on CE (Forlini 
and Racine, 2009b).  In this paper, five themes around the non-medical use of 
MPH for performance enhancement are reported and discussed: (1) stakeholder 
reactions to CE; (2) stakeholder views on common analogies; (3) descriptions 
(definitions) of and views on CE; (4) physiological effects, psychological effects 
and safety of MPH use for CE; (5) stakeholder impression of media coverage on 
CE. 
Results 
Demographic data 
Sixty-five individuals participated in one of nine homogeneous focus group 
discussions: 29 students (mean age 20.9 years; focus groups A, B, C); 21 
parents (mean age 53.8 years, focus groups D, F, H) and 15 healthcare 
providers (mean age 31.9 years, focus groups E, G, I). Each participant was 
assigned an alphanumeric code (e.g., A1) where the letter identified the 
stakeholder group they belonged to and the number indicated the order in which 
they were recruited. Results from the demographic questionnaire (Table 4.1) 
show that the majority of participants were female (68%; N=44/65; S: N=22; P: 
N=12; HCP: N=10) and had obtained or were in the process of obtaining 
undergraduate or graduate degrees (86%; N=57/65; S: N=29; P: N=15; HCP: 
N=13). The commercial name of MPH, Ritalin, was used in the questionnaire 
because of its familiarity. The remaining results from the questionnaire are 
presented in Table 4.1 which include the participant’s experience with MPH in the 
medical (questions 1, 2 and 3) and non-medical (questions 4, 5 and 6) contexts 
as well as the participant’s appreciation of the media and their interest in popular 
science issues (questions 7 and 8). 
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Table 4.1: Demographic data and participants’ experience with the medical and non-medical contexts of MPH use as well 
as appreciation of media and popular science 
 
Question 
 
Yes (%) 
S P HCP Total 
1. Do you presently have a prescription for Ritalin? - - - 0 
2. Have you ever had a prescription for Ritalin? - 10 - 3 
3. Do you know someone with a prescription for Ritalin? 48 29 53 43 
4. Have you ever tried Ritalin for non-medical uses? 24 - - 11 
5. Do you know someone who has tried Ritalin for non-medical uses? 69 5 33 40 
6. Had you ever heard/read about Ritalin for non-medical purposes before participating in this 
project? 90 67 53 74 
7. Do you subscribe to a newspaper or magazine? 38 67 33 46 
8. Are you interested in reading about popular science? * 93 80 93 89 
S: students; P: parents; HCP: healthcare providers *64 respondents answered this question 
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Stakeholder reactions to the non-medical use of MPH for performance 
enhancement 
Reactions toward the non-medical use of MPH varied across groups of 
stakeholders (Table 4.2). Some were surprised, even shocked to learn about 
performance enhancement in the academic setting; others, namely students, 
were not surprised given the lengths to which students will go to in order to 
succeed. The perspectives of parents and HCP were marked by the presence of 
two features. The first was a strong association of MPH exclusively with the 
medical context, which created some confusion about how MPH could actually 
be used non-medically. The second was a reaction of surprise caused by the 
perceived frequency and extent of non-medical use of MPH. Some parents were 
surprised that the non-medical use of MPH was socially acceptable among 
students but also stated that it was not the first time substances were used to 
improve performance. Students suggested that MPH had become a common 
solution for students wanting to improve their performance but some students 
were also surprised that a neuropharmaceutical like MPH was being used to 
enhance performance. The dual reactions of students were interesting because 
many participants had first hand experience with the non-medical use of MPH. 
For example, student C10 said, “I would see my roommate crash from it. I knew it 
was happening.” Many students were aware of CE before attending the focus 
groups. As a result, among students who were surprised, many referred to their 
impression regarding MPH use for performance enhancement the first time they 
heard of it (during their studies) and not necessarily their reaction to the focus 
group and the focus group prompt material.
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Table 4.2: Features of stakeholder reactions with qualitative examples toward the non-medical use of methylphenidate for 
performance enhancement 
 
Features of stakeholders’ surprise and shock about the non-medical use of MPH 
Description Lengths to which students would go to 
perform well (S, P, HCP)* 
Association of MPH with the medical 
context (P, HCP) 
Perceived extent, 
frequency (P, HCP), and 
social acceptance (P) of 
non-medical use of MPH 
for CE 
Examples “I found out about it last year like 
students in my classes were taking 
Ritalin and I was really surprised, like 
“What do they need this for?” and since 
then I’ve known more, not more and 
more people necessarily, but it seems 
to be the norm now.” (Student A6) 
 
“Yes, really. It shocked me, you know, 
because I never thought it went that 
far.” (HCP I1) 
“Well I know that young kids, in 
primary school, take a lot of Ritalin, 
and secondary school too. But I 
thought it was only for medical 
purpose, given by the doctor. I was 
shocked.” (Parent F2) 
 
“I was very surprised because it is 
like abusing it. It used to be 
something prescribed. You used to 
take it for overactive children and 
now it is used to enhance your ability 
to perform.” 
(HCP E7) 
“I was more shocked than 
surprised by the moral 
ambiguity when some 
people think it is OK.” 
(Parent H5) 
 
“I wasn’t expecting that 
students were cheating 
this way, but sure I 
thought maybe 0.5% of 
students, but we have 
some statistics of 5%, 
something like that.” (HCP 
E3) 
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Features of stakeholders’ lack of surprise about the non-medical use of MPH 
Description Students will go to great lengths to 
perform well (S) 
MPH has become a common solution 
for 
students (S) 
MPH is not the first 
substance to be used to 
enhance performance 
(P, HCP) 
Examples “I just found out about this a few months 
ago but when I found out about it I 
wasn’t necessarily surprised. Just sort 
of with the pressures of being in 
university and seeing a lot of friends 
crack under the pressure. A lot of 
students will go to great length and do 
almost anything to sort of enhance their 
academic achievement.” 
(Student B10) 
“I had first heard about it, I guess, 
half way through my undergrad (...). 
Back then yeah it surprised me in a 
“What do you mean? This is so 
unfair!” way because there was quite 
a bit of students using it (…). Back 
then I was surprised but now, quite 
frankly, it seems that it, everybody, it 
kind of got out there, got the 
message.” (Student A9) 
“Not surprised but in the 
1960s and 70’s, ah, 
students used coffee, 
cigarettes, and nowadays 
there are a lot of 
possibilities to use drugs.” 
(Parent F7) 
MPH: methylphenidate; S: students; P: parents; HCP: healthcare providers 
*Parentheses indicate that this feature was expressed by at least one participant of this group 
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Table 4.3: Stakeholder reactions to analogies to performance-enhancing 
steroids and caffeine in reference to the non-medical use of MPH * 
 
 Steroids Caffeine 
Same Steroids and MPH are used for 
the same type of goal (S, P, 
HCP) 
Taking either MPH or steroids 
constitutes cheating (S, P, 
HCP) 
Caffeine and MPH both 
have a risk of dependence 
and are used to improve 
performance (P) 
Different Steroids improve physical 
performance more than MPH 
improves concentration (S) 
MPH can be taken occasionally 
while steroids require long-term 
use (S) 
Athletes are more commonly 
regarded as role models than 
academics (S) 
Different regulation  for the use 
of substances in sports and 
academics (HCP) 
Caffeine does not have the 
same effect on 
concentration as MPH (S) 
 
MPH is not available over 
the counter like caffeine 
(HCP) 
Ambivalent Unsure whether the use of 
steroids in competition and the 
non-medical use of MPH are 
both cheating to the same 
extent (S) 
Unsure whether the 
regulation of caffeine and 
MPH make them equivalent 
given that the goals 
underlying their 
consumption by students 
are the same (S) 
*Parentheses indicate that this feature was expressed by at least one participant of this 
group 
 
Stakeholder views of common analogies for the non-medical use of MPH 
for performance enhancement 
Table 4.3 summarizes the different attitudes (“same”, “different”, and 
“ambivalent”) expressed by stakeholder groups toward analogies between 
the non-medical use of MPH and the use of other substances like 
performance-enhancing steroids in sports or caffeine (coffee) in the 
academic environment. There was no general consensus within and 
between groups on the similarities and differences between MPH and 
these other substances. We found the views voiced by stakeholders to be 
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complex and sometimes paradoxical. In general, stakeholders were 
hesitant to consider the use of MPH as completely analogous with the use 
of other performance enhancing substances. The student group was 
especially ambivalent about whether the analogies of MPH to steroids and 
coffee were fair or accurate. In addition to Table 4.3, the text below 
provides qualitative examples of these views to illustrate how stakeholders 
compared and contrasted MPH to steroids and coffee. 
Stakeholders considered MPH comparable to performance-enhancing 
steroids 
Some participants from all three stakeholder groups agreed that using 
MPH as a study aid was akin to using performance-enhancing steroids in 
sports because, in both contexts, the goal is to improve performance. HCP 
E1 described this goal as “hyper-functioning” because “you are functioning 
and you want to function better.” In further support of this analogy, both 
sports and academia were viewed as competitive environments. The 
competition in both fields was compared by Student A2 who said that in 
sports “[y]ou want to beat the teams (…) otherwise they will replace you” 
and in academia “you need that ‘A’ because (…) there are so many just 
like you who can get your spot.” Stakeholders with this point of view also 
agreed that the non-medical use of MPH to improve performance would 
constitute cheating. Student C6 qualified this perspective by explaining 
that, “[i]n both cases it is an artificial chemical enhancement” because 
“academic performance is sort of based on merit and hard work, which is 
the same thing in professional sports, based on natural ability and also 
hard work.” Some participants from all three groups considered that, by 
virtue, a substance used as shortcut to perform in a competitive 
environment renders MPH the same as using steroids.  
Stakeholders contrasted MPH and steroids 
During the focus group, students and HCP identified some aspects that 
differentiated the contexts in which MPH and performance-enhancing 
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steroids are used. They described enhancing athletic performance as 
having implications for professional advancement whereas enhancing 
academic performance impacted a student’s future. Differences were also 
discussed by students and HCP regarding the nature of competition in 
sports and academics. For example, sports competitions were regarded 
as a “celebration of the natural body and how far the natural body can go 
(…) without enhancement” (Student B8) and as having extraordinary 
expectations for achievement,  “(…) I don’t know if you can compare a 
baseball player taking steroids because he wants to beat the home run 
record as opposed to a student that takes Ritalin so that he can pass his 
exam and get a decent job and make a living out of it” (Student A1). 
However, one HCP highlighted how the “ordinary” nature of academic 
achievement renders academic success all the more important, “if you are 
not succeeding in sports you can do other things. (…). If you are failing in 
school and have low grades your life is quite impaired for a long time” 
(HCP I1). Another HCP also added the fundamental difference on which 
sports competitions are currently regulated, “[t]hey know that there is 
going to be drugs tests and urine tests in baseball” (HCP G4). In contrast, 
academic competition was described as “how well you want to do and 
what grade you want” (Student B5) without “a focus on what’s natural” 
(Student B2).  
The contexts of academia and sports were further distinguished by 
students in terms of physiological targets because, “(…) if you’re on 
steroids (…) you can do things that people can’t do no matter what if they 
weren’t on steroids. (…) as far as I can tell, Ritalin (…) could [help] 
achieve the same level of performance [as someone who has not taken 
MPH]” (Student A4).  Another aspect that appeared to influence students’ 
appreciation of the analogies was the frequency of substance use, “you 
have to keep taking steroids for a very long period of time to keep that 
muscle mass” but MPH can be used occasionally at “specific times” 
(Student A5). Some students further distinguished academia and sports by 
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describing that sports figures are “idols to society” and this may explain 
“why society thinks that steroid use is negative for athletes” (Student B8). 
In sum, some participants in all three stakeholder groups thought 
academic and sports competitions shared a common goal but differences 
between MPH and steroids in particular were highlighted in terms of the 
contexts and purposes for which the substances are used.  
Stakeholders compared MPH and caffeine 
The use of caffeine as an analogy to the non-medical use of MPH was 
less debated than the steroid analogy yet it yielded some interesting 
comparisons and contrasts. The similarities of MPH to caffeine were 
mainly expressed by parents. Methylphenidate and caffeine were both 
considered substances which have the potential to cause dependence. 
However, parents recognized that despite this commonality, the contexts 
of MPH and caffeine use were different. Parent D5 expressed this 
observation by saying: “[s]ociety doesn’t get upset when somebody uses 
caffeine to stay awake. Even though it is a drug it is acceptable.” Parents 
also regarded MPH and caffeine as similar study aids because: “[t]he kids 
who do not take Ritalin (…) get a huge latté or whatever it is. (…). So if 
they don’t take Ritalin they will take coffee, they take Red Bull, they take 
something” (Parent H2).  Thus, some parents regarded MPH and caffeine 
as drugs that are both used in the academic context.   
Stakeholders contrasted MPH and caffeine 
Students and HCP contrasted MPH and caffeine more than parents did. 
The first difference was brought up by students who considered the 
physiological and psychological effects of MPH and caffeine to be 
different. For example, Student C10 said that, “I don’t think that caffeine 
helps you concentrate. I just think that it makes you jittery and not able to 
fall asleep.”  Thus, for students, the targets of MPH and caffeine appeared 
to be different as were the ways in which they can help a student improve 
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their academic performance. As with steroids, the regulation of caffeine, in 
comparison to MPH, was the major difference for HCP. They contended 
that coffee and energy drinks containing caffeine were available over the 
counter while MPH is a prescription drug that should not be used as 
readily for enhancement purposes. With potentially different effects on 
academic performance and involving different regulatory frameworks, 
students and HCP considered that performance enhancement with MPH 
was not equivalent to consumption of caffeine.  
Various stakeholder definitions of non-medical use of MPH for 
performance enhancement  
Stakeholders offered incongruent definitions of the non-medical use of 
MPH. Based on a published discourse analysis (Racine and Forlini, 2010), 
three terms (“abuse”, “enhancement” and “lifestyle”) were proposed as 
prompts for the discussion of definitions. Stakeholders associated the non-
medical use of MPH with all three terms. Some stakeholders, through the 
process of elimination, determined which of the three terms corresponded 
most to their perspective. For example, Student C9 preferred the term 
enhancement being unsure of, “[going] as far as calling it abuse. Lifestyle 
sounds kind of soft for [them]. Enhancement [they] think works.”  Similar 
rationales are, “(…) abuse (…) sounds too much” (Student C1) or, “(…) 
that’s probably more enhancement than it is abuse” (Student B2). 
Stakeholders also combined terms giving definitions like, “it kind of falls 
somewhere in between abuse and enhancement” (Student C6). Finally, 
some stakeholders maintained that “(…) you [can’t] necessarily separate 
any of these three concepts from the issue (…)” (HCP I3). 
Generally, terms were selected in relation to specific features of the 
non-medical use of MPH. For example, Student A5 explained that, “(…) 
the difference between these three categories: abuse, enhancement or 
lifestyle is how [MPH is] taken, how often [MPH is] taken, what are the 
motives in general.” Abuse and enhancement were the definitions most 
elaborated upon. Some members from each stakeholder group, mostly 
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HCP, defined the non-medical use of MPH as abuse, i.e., usually defined 
as the lack of adherence to MPH’s medical label. For instance, the non-
medical use of MPH was classified, “(…) as abuse just on the fact that 
[MPH] is a prescription drug. Coffee and Red Bull you can buy in a store 
and it is legal but I mean [MPH] is under the table. That is what crosses 
the line” (HCP G7). The use of MPH without a prescription in healthy 
individuals also troubled stakeholders. HCP E7 elaborated by saying that, 
“(…) this is abuse or self-medication because they don’t use it for the 
purpose it was made.” Included in the abuse definition were the 
perspectives that non-medical use of MPH was caused by peer pressure 
and that it constituted cheating.  
When defined as enhancement, stakeholders emphasized that the 
non-medical use was purposeful because, “(…) the first assumption is that 
people are taking it to better enhance their concentration” (Student B5). 
The fact that healthy individuals, as opposed to patients, were using MPH 
was also a feature of the enhancement definition but some stakeholders 
nuanced that these individuals were building upon abilities they already 
had because they, “(…) still have to learn the information this just makes 
[their] brain think in a certain way” (Student C4).  Some students 
highlighted that because non-medical MPH use by students pertained to 
certain types of goals it was typically occasional and not necessarily 
constitutive of a student’s life. However, some students and HCP 
explained that the use of MPH to improve academic performance could 
become a lifestyle choice if a dependence develops, “(…) you are taking 
these pills and you can’t write without taking them” (Student C2).  
A few stakeholders combined terms to form a definition. The two 
most prominent combinations were abuse-enhancement and abuse-
enhancement-lifestyle. The association of abuse and enhancement 
described how students, “(…) might use it once but along the same lines 
as caffeine (…) caffeine can be abused too. Any drug can be abused and 
so; if it becomes obsessive then it becomes abuse” (Student C6). When 
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adding the lifestyle component to a composite definition, stakeholders of 
this opinion perceived the definition to include a “(…) choice puts you at an 
advantage over someone who chooses not to do that” (HCP I3). A 
composite definition could describe the non-medical use of MPH as 
striving toward an academic goal by making a choice to use a medication 
in a manner other than it is normally prescribed. Overall, stakeholders 
defined the non-medical use of MPH mostly in terms of abuse and 
enhancement. 
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Table 4.4: Risks and benefits of the non-medical use of MPH for 
performance-enhancement identified in prompt material and by 
stakeholders during focus groups  
 
Prompt material 
only 
Common to 
stakeholders 
and prompt 
material 
Stakeholders only 
 
Risks 
 
Depression linked 
to withdrawal, 
dizziness, loss of 
appetite, irritability 
 
Cluttering of 
the brain, 
heart attacks, 
heart 
palpitations, 
insomnia, 
nausea 
 
Anxiety, bad for the brain, 
depression, drug 
interactions, general 
cardiovascular effects, 
hallucinations, gateway 
drug, general health 
concerns, general mental 
health concerns, lack of 
self-esteem, missing out 
on learning skills, negative 
effects on nervous system, 
psychosis, stunting 
growth, sudden death, 
suicide, teratogenic 
effects, toxicity, weight 
loss, withdrawal from drug 
Benefits Accumulate more 
information in a 
shorter time, boost 
brain activity, 
increase 
confidence, 
increase energy, 
helps to organize 
thoughts, helps to 
think rationally, 
maintain high 
performance level, 
minimize fatigue 
Boost 
concentration
, increase 
focus 
Person appears more 
intelligent 
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Risks and benefits of the non-medical use of MPH identified by 
stakeholders 
Stakeholders identified and discussed a range of physiological and 
psychological risks and benefits of the non-medical use of MPH.  Risks 
and benefits identified by stakeholders were compared to those found in 
the prompt material they read before the focus groups. Table 4.4 shows 
the risks and benefits that were mentioned (1) exclusively in the prompt 
material, (2) common to both the prompt material and the focus groups 
and (3) exclusively during focus groups by stakeholders. There were no 
observable differences between stakeholder groups, but as a whole, 
stakeholders identified more risks than benefits of using MPH non-
medically. The discussion of benefits was more selective in the focus 
groups than in the prompt material. Stakeholders also discussed risks 
beyond those that were present in the prompt material. Only a few risks 
and benefits found in the prompt material were discussed in the focus 
groups. Thus, our results show that stakeholders emphasized the risks of 
non-medical use of MPH.  
Stakeholder reactions to safety of the non-medical use of MPH  
We asked participants whether they thought the non-medical use of MPH 
was a safe practice or if they had any concerns.. We found a split between 
the assessments that the non-medical use of MPH had either significant or 
limited risks. Two major factors contributed to the perspective that the non-
medical use of MPH was unsafe. First, stakeholders considered that many 
risks were still unknown and “from a pharmacological point of view, this 
drug has not [been] established and they have not studied long term 
effects” (HCP E3). Of the potential risks, emphasis was put on the, “(…) 
long-term effects that it would have on your body, especially if you become 
dependent on it and end up taking it all your adult working life” (Student 
C6). They added that this type of data would be difficult to obtain because 
the non-medical use of MPH happens outside of the medical and research 
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contexts. Stakeholders related this obstacle to a second factor, general 
lack of medical supervision. This lack was exacerbated by the fact that 
MPH is obtained notably through illegal channels such that the drug “(…) 
[does] not come with instructions” (Student A5) whereas “(…) if you were 
on a prescription presumably your doctor would be vigilant about 
monitoring the use and any potential side-effects and counter information” 
(Student C6).  Student C6 went on to describe the supervision of a 
medical professional as a “safety net” which is absent when one is “self-
medicating”. Furthermore, it was mentioned that without professional 
instructions or guidance, “(…) you really have to experiment to know how 
much [the drug] affects you” (Student C10). Thus, some participants 
feared the potential consequences of self-medication for non-medical 
purposes. 
In contrast to the ill ease with unknown risks, other stakeholder 
responses showed a sense of security with regard to the safety of using 
MPH non-medically. This sense of security was explained in several ways. 
First, stakeholders communicated a trust in substances that are subject to 
an official approval process, otherwise explained as “(…) a perception (…) 
that because it’s prescription medication and not a street drug that it is 
pretty safe (…)” (Student B2). An example of this point of view was, “I 
think when used responsibly it’s relatively safe otherwise they wouldn’t 
prescribe it” (Student B1). The second perspective had to do with MPH’s 
reputation as a pediatric medication. Parent F8 explained that, “[t]he fact 
that this is taken by children, perhaps students think that it is not serious to 
take this drug, you know. ‘If children can take it, it is fine with us.’”  It was 
assumed that the strict approval and prescription procedure for children, 
makes a drug like MPH automatically safe for other populations such as 
adults because, “(…) if it is a drug they have been giving to kids (…) that 
means it’s pretty benign” (Student B7).  Finally, stakeholders’ belief that 
non-medical use of MPH was safe indicated that regardless of whether a 
substance is available by prescription or over-the-counter individuals 
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should consume substances responsibly to avoid dangerous side-effects. 
To illustrate this point, Student B10 said, “(…) everything is sort of not safe 
if not taken in moderation even something like caffeine can have some 
serious effects that people don’t know about (…)”. Many participants with 
this point of view suggested that the key to responsible use was in 
moderation of the amount and frequency that a drug like MPH is used 
non-medically to strike “(…) a balance [in the] amount of times you take it, 
on a week (…) or how much a day or if you mix it with caffeine” (HCP G3). 
Accordingly, some participants characterized non-medical use of MPH as 
“relatively safe” (Student B1), “probably fine” (Student C11), “fairly safe” 
(Student C9) and “not necessarily dangerous” (HCP I3). 
Stakeholder appreciation of media coverage on non-medical use of 
methylphenidate for performance enhancement 
Part of the focus group discussion was devoted to assessing stakeholder 
appreciation of the media coverage on the non-medical use of MPH based 
on but not limited to the prompt material. Stakeholder opinions pertained 
to general aspects of the media coverage, the information contained in the 
articles and their perspective on the media coverage itself (Table 4.5). The 
three stakeholder groups, but especially parents, acknowledged that the 
media coverage on the non-medical use of MPH provided valuable 
information. However, stakeholders suggested that media coverage may 
promote the non-medical use of MPH simply by describing the practice. 
One healthcare provider offered the perspective that professionals who 
confirm the enhancing effects of MPH could influence the public. Some 
participants stated that the articles did not present enough reasons to 
discourage the use of MPH. Though most of the comments on the 
promotion of the non-medical use of MPH were in the third person, some 
participants employed the first person to indicate that they would try it. 
Students, in particular, wondered why media coverage had only recently 
begun discussing after years of MPH being used non-medically. Students 
were most critical of the style of the media coverage. For example, one 
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student said, “it kind of sounded like something that was in [their] high 
school newspaper” (Student B5).  
No stakeholders reported that the information in the articles was 
complete. Many suggested subjects that they would have liked to see 
covered more extensively (see column 2 of Table 5). Stakeholders formed 
a consensus on two information gaps: (1) the lack of information on the 
workings, effects and efficacy of MPH especially on healthy individuals in 
the long-term and (2) the debatable quality of the scientific evidence 
contained in the articles. Topics of interest also included accurate 
prevalence data, a more developed ethics debate, details about how one 
uses MPH non-medically and the solutions being explored to reduce the 
non-medical use of MPH. The last three subjects were specific to 
students, parents and HCP, respectively. 
The last aspect that stakeholders commented on was the 
perspective of the articles. Some participants from all three stakeholder 
groups considered the perspective of the articles to be ambiguous. These 
stakeholders stated that there was not enough discussion of the benefits 
and social acceptability of the non-medical use of MPH and, consequently, 
they could not make up their own minds. The majority view indicated the 
presence of a bias in the media coverage on the non-medical use of MPH. 
Stakeholders described a negative bias (media emphasized the risks of 
the non-medical use of MPH) and a positive bias (media focused on the 
benefits). Only one participant from each stakeholder group said that the 
articles were well rounded and balanced. A few students and HCP noted 
that the media coverage was realistic, even if ambiguous, because it 
reflected the current state of social opinion on the non-medical use of 
MPH.
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Table 4.5: Stakeholder opinions with qualitative examples on the media coverage of the non-medical use of MPH for 
performance enhancement (in terms of general appreciation, completeness of information and perspective of the media)*† 
1. General comments on media coverage of the non-medical use of MPH 
A. Positive appreciation of media coverage on non-medical use of MPH (S, P, HCP) 
• “I think it’s important to send the message out there you do not need Ritalin to get through things.” ( Student 
A9) 
• “I found it very interesting to be aware of what is going on on campus because (…) I was not aware of it.” 
(HCP I1) 
B.  Criticism of the timing of media coverage on the non-medical use of MPH (S) 
• “I remember reading about this in a teenage magazine when I was 13. This has been a problem for ages. I 
don’t see why there is news coverage announcing it as a new problem.” (Student C10)  
C. Media coverage may encourage non-medical use of MPH (S, P, HCP) 
• “I don’t know if spreading it all over the newspapers is a good idea because quite frankly I think it kind of 
promotes it.” (Student A9) 
• “I think unintentionally it would sort of promote Ritalin use to students.” (Student B2) 
• “I would probably be more likely to take Ritalin now after reading those articles than not because if like the 
only side effect they can come up with, and I think those articles were slanted pretty negatively, was that my 
brain can get too full. Like, you know, maybe I’ll try it.” (Student B7) 
• “I don’t know why but it made me want to try Ritalin.” (Student B8) 
2. Comments on incomplete information on the risks and benefits of the non-medical use of MPH 
A. Workings, effects and efficacy of MPH (S, P, HCP) 
• “I would have liked more content about neuro-physiology and how the pill is actually working. What are the 
studies that have actually been done? I would have liked more scientific evidence base. (…) I would have 
liked more things to help me to make my mind up about the medication because after reading the articles it 
was difficult for me to say yes or no, do I agree do I disagree?” (HCP E2) 
• “It was kind of just like a surface of what was going on and not really delving into it or really what Ritalin 
does.” (Student B5) 
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• “I would be interested to read about the student who took it like recreationally or whatever and something 
bad happened to them like that’s what I really want to know before I try it, like what’s the worst that could 
happen?” (Student B7) 
• “it would have been nicer to have sort of stronger scientific view as well or just an article that explains what 
Ritalin physiologically does to your body because not everybody knows.”(Student B10) 
• “it is about the short time effect, not the long term effect. There is nothing; there is nothing about long-term 
effect.” (Parent H1) 
• “I don’t think it addresses at all the retention of the material [learned with Ritalin].” (Parent D1) 
B. Scientific evidence (S, P, HCP) 
• “all of them basically lacked the scientific information. There was no evidence for somebody who would be 
looking out for Ritalin and reading more about it. Maybe it might be complicated for an ordinary paper but 
there has to be at least some scientific evidence to be there because it was mostly anecdotal.” (Student A8) 
• “sometimes I wondered about the data in these statements and I wondered where it came from and what 
sample population it was tested on” (HCP G7)  
•  “it just shows you how bad the media are: no data just impressions, ‘I hear that, this and that.’” (HCP G1)  
C. Prevalence data (S, HCP)  
• “I kind of got a vague feeling of actual prevalence and the actual size of the problem because here’s one 
student from [Quebec], she thinks her friends use it. Here’s another student from Ontario… This is not very 
good sampling really if you want to find out how much we have to be worried about this.” (Student B2)   
D. Ethics debate (S)   
• “(…) other articles didn’t really address the ethical issues as much. That is what leapt out at me the most. 
The articles were more straight on news articles whereas they don’t really talk about the nuanced issues 
about it.” (Student C6) 
E.   Access to of non-medical use of MPH (P) 
• “Is it that easy to get those drugs? Do you need a lot of money to get those drugs? We don’t know about 
that, how these people get the drugs.” (Parent F2) 
F. Solutions to non-medical use of MPH (HCP)  
• “(…) where were the solutions? Where were the ‘Hey, this is a problem! Why is this going on?’ What are we 
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going to do about it?” (HCP G4) 
3. Comments on the perspective of media coverage of the non-medical use of MPH 
A. Ambiguous discussion on benefits and acceptability of the non-medical use of MPH (S, P, HCP) 
• “the article in all aspects it is really inconclusive. It doesn’t really say where it is good, it doesn’t really say 
where it is bad. All it really says is that it enhances. Does it enhance?” (Parent D5) 
• “I think that there seems to be this recurrent theme that when discussing things like Ritalin and performance 
enhancement drugs or substances that there does seem to be something intuitively disconcerting (…) 
people have a lot of difficulty articulating why they feel that it’s wrong or why they feel that people shouldn’t 
be doing it. (…) it’s hard to come up with some definitive reason as to why it’s wrong and that’s why I 
personally think that’s why a lot of people indulge. And that’s what I think B7 was saying about the articles 
that they seem to be getting to something about there being some nebulous connotation but nobody could 
quite pinpoint what as wrong.” (Student B1) 
B. Bias in coverage of the non-medical use of MPH (S, HCP) — majority 
• “Another problem that I had with the articles is that they really didn’t focus on Ritalin in schools as a social 
topic. They didn’t say that it is a reflection of what we expect from our kids or it is a reflection of the current 
job market and what they are looking for. It was just like ‘they’re doing it. It’s bad. Save your children!’” 
(Student C11) 
• “What I didn’t like about the articles is that they all made the assumption but it kind of became an assertion 
that taking Ritalin makes you perform better.” (Student A5) 
C. Unbiased coverage of the non-medical use of MPH (S, P, HCP) — minority  
• “I think they were quite neutral at exposing the facts.” (HCP E1) 
D. Realistic coverage of the non-medical use of MPH (S, HCP) 
• “I think they kind of portrayed how grey of an issue this is that there are many different takes on it that there 
are many different aspects to it. I think they did pretty well for being a page and a half each.” (Student B1) 
MPH: methylphenidate; S: students; P: Parents; HCP: healthcare providers 
*Qualitative differences between stakeholder groups are explained in the text  
† Parentheses indicate that this feature was expressed by at least one participant of this group 
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Discussion 
This study examined how different stakeholders consider the phenomenon of non-
medical use of a common stimulant, a practice often called cognitive enhancement in 
the bioethics literature. First, though the majority of participants were already familiar 
with the non-medical use of MPH, many expressed considerable surprise and even 
reported being shocked when learning about its existence. Second, our study 
revealed marked ambivalence and pluralism in the perspectives of stakeholders with 
regard to the non-medical use of MPH to improve performance from both descriptive 
(what is going on) and normative (what should we do) standpoints. For example, no 
consensus was reached to the effect that non-medical use of a stimulant like MPH 
could be described as “cognitive enhancement”, “abuse of a prescription drug” or “a 
lifestyle choice”. Stakeholders responded to popular analogies of performance-
enhancing steroids and caffeine by comparing and contrasting certain features of 
these substances but hesitated to declare either of them normatively equivalent to 
the use of MPH. Finally, in contrast to previous studies (Forlini and Racine, 2009a) 
this study did not find substantial differences in opinion between different stakeholder 
groups. Media coverage of the non-medical use of MPH was appreciated by 
stakeholders but also considered as potentially encouraging non-medical use and 
lacking in certain types of information and a clear or balanced position (mostly by 
HCP and students).  
Limitations 
Some aspects of the qualitative nature of this project should be taken into 
consideration for their proper interpretation.  First, due to the small sample, the 
opinions expressed in the focus groups are not representative of general opinions of 
students, parents and healthcare providers, especially outside of North America. 
Though the UK and Australia media are represented in this prompt material, the way 
in which CE was depicted reflected a largely North American phenomenon. Second, 
participants were given four representative media articles to read prior to the focus 
group.  Despite the range of topics covered in these articles, such prompts have 
advantages (e.g., real source of information intended for general readership) and 
disadvantages (e.g., not addressing in detail every ethical and social issue related to 
cognitive enhancement). Third, focus groups are discussions and not surveys. Not 
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all participants answered every question thus when we report the perspectives 
expressed, these perspectives should be considered as those that were explicitly 
and de facto expressed – not necessarily all that could be expressed. Fourth, our 
focus groups were conducted in English (given the English-language prompts) but 
our recruitment included individuals with different mother tongues which could have 
an impact on how participants expressed themselves. Fifth, some difficulties in data 
capture (e.g., failed recordings of some comments) and subsequent transcription 
caused a very small part of participant statements to be unsuitable for analysis. 
The results presented in this article bring to light two points that can be further 
discussed. First, we reflect upon the role of stakeholder ambivalence in the debate 
on the non-medical use of MPH. Second, we examine how analogies can be useful 
to dispel ambivalence but can also mislead in the CE debate.  
Ambivalence: indicator of indifference and misunderstanding or a reflection of deeper 
concerns? 
Our study revealed fundamental ambivalence and pluralism of stakeholders with 
respect to descriptive and normative aspects of CE. The ambivalence we noted 
reflects the coexistence of conflicting reactions and perspectives ("ambivalence, n," 
1989) expressed by stakeholders in defining CE, deciding upon its acceptability, and 
determining its equivalence to common analogies. There are at least two major 
interpretations of this ambivalence. First, ambivalence may reflect a lack knowledge 
and exposure to CE among stakeholders. This is likely partly true as some 
stakeholders expressed surprise about the sheer existence of CE with MPH or about 
the extent of this practice. Such an interpretation is consistent with the unidirectional 
model of science communication which “assumes that researchers are in control of 
media content and are the primary gatekeepers of scientific knowledge” (Racine, 
forthcoming). This model also suggests that sound science communication is 
hindered by an information gap between experts and non-experts (Racine, 2010). 
However, most stakeholders were familiar with CE before the focus groups (see 
questionnaire data of Table 4.1) and were still able to elaborate and discuss a wide 
range of issues associated with CE. Stakeholders in our study demonstrated 
advanced understanding of the consequences and implications of CE during the 
discussion, going beyond the prompt material to attempt a definition and discuss the 
risks and benefits of CE.  
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A second interpretation is more consistent with multidirectional approaches to 
science communication. The multi-directional model encourages open dialogue and 
self-reflection between and among stakeholders (science, humanities, public and 
media) (Racine, 2010). This approach considers that ambivalence may actually 
reveal something much deeper than mere lack of knowledge, or expertise. Though 
there were few dominant opinions, stakeholders provided original perspectives 
regarding the debate on CE. Thus, the ambivalence may reflect that stakeholders 
sense that CE could carry substantial issues and constitutes a source of discomfort. 
Hence, a more compelling interpretation is that stakeholders felt uneasy about the 
social implications of CE in academic and work environments as well as the larger 
but vexing role that pharmaceuticals could play in helping individuals cope with 
increasing social demands for performance. This interpretation, more consistent with 
our findings, also suggests that stakeholders have felt the scope and far-reaching 
social implications of changes that broader scale CE would bring about. Given this 
capacity and interest of stakeholders, several authors have suggested 
multidirectional approaches to include stakeholder experiences in debates about 
ethical and social issues associated with neuroscience (Illes et al., 2005; Illes et al., 
2010; Racine et al., 2005). As stated by Leshner (2004), “[t]he unique attributes of 
the brain as an organ system and its centrality to our concept of our own humanity 
raise an array of ethical issues that must be resolved in an open dialogue involving 
both the scientific community and the wider public before we will see widespread 
application of the fruits of neuroscientific progress.” 
Interestingly, the ambivalence of our focus group participants contrasts quite 
radically with the often strong and clear-cut pro and con positions encountered in the 
bioethics literature. Optimists predict that CE can positively and substantially 
contribute to society (Bostrom and Sandberg, 2009).  They suggest that CE could 
equalize the natural distribution of abilities and talents at the source of some 
injustices in opportunity (Savulescu, 2006). Individuals who wish to maximize their 
performances could decide autonomously to do so (Caplan and Elliott, 2004; Caplan 
and McHugh, 2007). Using pharmaceuticals for CE has been argued to be “morally 
equivalent to other, more familiar, enhancements” such as “education, good health 
habits and information technology — ways that our uniquely innovative species tries 
to improve itself” (Greely et al., 2008). These points of view lay the groundwork for 
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the public to accept an ideal situation of a society of enhanced individuals but it fails 
to capture the ambivalence expressed in our focus groups. 
The critics of CE have expressed – like proponents of enhancement – strong 
opinions. One of their main arguments is that CE represents an affront to “human 
nature” and bypasses the enrichment of life experiences gained by hard work and 
renders such achievements inauthentic (President's Council on Bioethics, 2003).  
Sandel (2004) invites us to recognize that, “our talents and powers are not wholly our 
own doing”, a framework he calls “giftedness” and has been dubbed “gratitude” by 
Parens (2006). Arguments against CE have garnered the reputation of being 
inarticulate and largely unpersuasive because they are based on ill-defined concepts 
such as “human nature” and emotional reactions (Caplan and Elliott, 2004; Caplan 
and McHugh, 2007; Nature, 2007). As a result, criticism or uncertainty regarding CE 
has not been brought to the forefront and therefore, much ambivalence that could be 
expressed in the literature has dissipated under the radicalization of the debate 
between those in favor and those against CE. Bioethics writings on this topic seem 
to be driven by what Dewey called a “quest for certainty”. 
One exception can be found in the writings of Erik Parens who has attempted 
to reconcile the academic lenses of optimism and criticism of CE. Parens (2006) 
describes a “creativity” framework that emphasizes, “our responsibility to be creative, 
to use our creativity to mend and transform ourselves and the world” instead of 
accepting the gifts we are handed. Parens (2005) argues that  the creativity and 
gratitude frameworks are superficially opposing yet they have a shared vision of the 
“moral ideal of authenticity” (Parens, 2006). Consequently, Parens (2005) suggests 
that the “gratitude and creativity frameworks deserve equal respect and that we 
should aspire to balance the commitments and insights of both” in order to better 
consider the issues at stake in CE. In spite of its value for bridging arguments in 
favor and against CE, Parens’ proposal lacks realism with respect to the motivations 
underlying CE, especially the socio-economic forces at play and the pressures felt by 
members of society to respond to increased levels of performance (Forlini and 
Racine, 2009a). The fear is that, “the self-improvement agenda will be set not by 
individuals, but by powerful corporate interests” (Caplan and Elliott, 2004). The 
frameworks of creativity and gratitude too easily conceal the real politics and 
economic interests in the development of cognitive enhancers. 
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Another, more socially-grounded, way to capture the ambivalence of 
stakeholders can be articulated as a tension between the concepts of “moral 
acceptability” and “moral praiseworthiness” proposed by Racine (2010).  In 
Pragmatic Neuroethics, Racine proposes two “moral tests” to determine both the 
moral acceptability (i.e., is it ethically acceptable to pursue CE? Can an individual 
enhance their cognition?) as well as the moral praiseworthiness of CE (i.e., should 
an individual enhance their cognition? Is this a moral ideal?). Moral acceptability as 
proposed by Racine (2010) requires that fundamental scientific, ethical, social and 
policy criteria be met such as safety, respect for autonomy, fair resource allocation, 
and development of surveillance for CE. However, being deemed morally acceptable 
is only one condition to being morally praiseworthy. Moral praiseworthiness goes 
beyond the wishes of individuals seeking performance enhancement to consider 
broader goals such as addressing the medical needs of humankind. Following these 
concepts, the ambivalence of stakeholders reflects their hesitation to declare CE 
morally acceptable since many conditions of moral acceptability are currently not 
met. For example, reliable scientific data remains to establish the safety, risks and 
side effects of cognitive enhancers. Ethical and legal conditions such as the freedom 
from coercion and mitigation of discrimination as well as cultural and social 
conditions such as the impact of CE on public health issues and health coverage 
have yet to be fulfilled (Racine, 2010). In addition, participants are perplexed about 
the moral praiseworthiness of CE. They are troubled by the prospect of a society 
where success in education and professional life would rely on or require the use of 
cognitive enhancers.  
The dyads of creativity-gratitude and moral acceptability-moral 
praiseworthiness proposed by Parens and Racine, respectively, have their own 
strengths and weaknesses. Their common value is to highlight that the type of 
ambivalence expressed by stakeholders in our study has potential deeper meaning 
than simple lack of knowledge. It is a sign of moral unrest, i.e., that ideal morals of 
gratitude, creativity and moral praiseworthiness are troubled by the prospect of 
broader scale CE. As both Parens and Racine point out in the CE debate, rarely can 
all aspects be explained and supported by only one framework or one moral 
construct. Both suggest that broader consideration of alternate frameworks is the 
way forward (rather than settling in one framework or relying on a single “moral 
test”).  
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At this point in time, it is unclear which lens or moral construct would most 
accurately capture the experiences and perspectives of stakeholders. Ambivalence 
on the part of stakeholders may reflect the very nature of the CE debate and the fact 
that issues at stake are captured in different lenses and frameworks.  Therefore, 
stakeholders and non-experts may carry some important wisdom in sensing what 
challenges broader scale CE would bring about. They are well positioned to gain 
contextual knowledge allowing them to assess the impact of CE in their context and 
lives. Those in favor of CE in the bioethics community can speculate how society 
could be improved but they do not have a privileged position to capture the 
experience of pressures and discomfort that CE carries. Pressures will mount for 
clearer and more articulate public opinion and policy approaches. Dismissing public 
perceptions too quickly may engender yet simply remaining ambivalent about 
descriptive and normative aspects could demonstrate complicit acceptance of broad 
scale CE.  However, the moral unrest that underlies stakeholder ambivalence about 
CE may also conceal an additional challenge. Stakeholders must consider and 
contextualize with sufficient time different features of CE before they can assess 
what the issues and impacts will be.  
Analogies: informing or distorting ethics debates? 
We noted various reactions and understandings of commonly-used analogies 
comparing performance enhancement with MPH to steroids or caffeine in our data. 
When dealing with fuzzy or difficult to comprehend phenomena, one obvious 
strategy consists of comparison to an allegedly better known phenomenon. In this 
regard, analogies are attractive conceptual tools that help grasp a theoretical 
phenomenon or process (target domain) by comparing it with a more familiar 
phenomenon or process (source domain). This approach has been described in 
great detail in cognitive science by Johnson and Lakoff (1980) as well as in ethics. 
Proponents of analogical thinking have argued for the prevalence and general worth 
of these forms of reasoning and thinking in ethics and beyond (Heath and Heath, 
2007). By calling upon familiar concepts and experiences, analogies can reduce the 
need for background information about a phenomenon. They have also been 
credited with making messages more concrete; favoring their comprehension and 
assimilation by non-experts.  
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Stakeholders in our study discussed the use of analogies in comparing 
caffeine and steroids with MPH. The process of comparing and contrasting a source 
domain to the target domain helped to dispel some of the normative ambivalence in 
comparing steroids and caffeine to MPH. Nonetheless and despite their penetrance 
and convenience as cognitive short-cuts, analogies can become problematic if they 
lack the crucial features of a target domain and therefore confuse rather than 
enlighten the understanding of a phenomenon.  
First, though analogies can be helpful to highlight features of a social 
phenomenon like the non-medical use of MPH, they can rarely capture the whole, or 
truly unique aspects, of the target domain. For instance, social context and social 
aspects may differ significantly between the source and the target domains. 
Participants in our study pointed out many differences in the environments and 
pressures enticing steroid use and caffeine use in contrast to the non-medical use of 
MPH. However, the analogies of caffeine and steroids to MPH are largely based on 
comparing the substances and not the circumstances in which the substances are 
taken. By focusing on the substance, the analogy may be masking social issues that 
are proper to the target phenomenon but absent in the source domain while doing 
further injustice to the broader social issues. For example, a prior study has also 
shown that social pressures to perform play a role in the non-medical use of MPH 
(Forlini and Racine, 2009a). Furthermore, many of the risks and benefits discussed 
in the focus groups and literature are physiological. Aside from the obvious benefit of 
increased cognition, there is little data on how CE affects interpersonal relationships. 
Perhaps these effects could be even more substantial than the physiological effects 
and risks. After all, if CE does not benefit how we are, who we are and where we are 
in society why would it even be practiced? Thus, without taking into consideration the 
social context, current analogies remain loose comparisons with important 
limitations. 
Second, differences in perspective can also compromise the congruency of 
value-laden analogies to a new phenomenon. Comparison of steroid and caffeine 
use to MPH provides an example of how analogies can capture opposing values. In 
our focus groups, steroids are generally frowned upon while caffeine is widely 
accepted yet both were commonly considered equivalent to MPH use. Using value-
laden analogies can prematurely attribute a certain value to an active debate such as 
CE. The salience and interpretation of value-laden analogies can also depend upon 
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the unique perspective of different stakeholder groups. The importance of regulation 
of substances played an important role in HCP opinion on the equivalency of 
analogies to the non-medical use of MPH. Students, on the other hand, focused 
more on the goals underlying steroid and caffeine use to compare them to MPH. 
Considering the varying interpretations of analogies by stakeholders, with sometimes 
contradictory values and opinions, agreeing on a definition is a challenge and 
evidence of a descriptive type of ambivalence.  
The use of analogies in an ethical and social debate such as CE is therefore 
vexing for several reasons. They are potentially useful discursive devices but also 
potentially misleading and unreliable grounds to base values and decisions upon. 
Analogies can lead both descriptive and normative perspectives of the target domain 
astray. First, a normative perspective on CE can hardly be considered without a 
multi-faceted approach to describing and understanding a specific situation, i.e., 
considering the social context and specific circumstances of the case (Jonsen, 
1991).  Second, the type of analogies used could also complicate reflection from a 
health-policy perspective. Consider a public health intervention based on an analogy 
of MPH to caffeine, a legal and largely accepted substance. On the other hand, 
consider a public health intervention, which equated steroids and MPH, a substance 
that is controlled and largely banned for enhancement purposes. The resulting public 
health interventions would send contradictory and even opposing messages to the 
public while failing to reflect how CE would actually affect their lives. 
Conclusion 
This paper reported a study of stakeholder perspectives on the use of MPH for CE. 
First, we found marked ambivalence in stakeholder perspectives, a clear contrast to 
most bioethics discourse which stands strongly in favor or against CE. We argued 
that there is a more profound meaning to stakeholder ambivalence indicating 
apparent discomfort of stakeholders with the economic and social pressures 
underlying the drive for cognitive enhancers. Second, we observed that common 
analogies used by academics and the media in the CE debate could be discursive 
devices that help dispel ambivalence regarding a new phenomenon (target domain). 
However analogies may neglect some of the distinct circumstances of CE practices 
fostering unclear interpretations from a stakeholder point of view and tempering 
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suggestions that analogies are useful in ethical debates. Public dialogue could help 
voice the unease of stakeholders and also avoid hastily opting for permissive or 
restrictive health policies for CE without taking into full consideration current 
concerns in the public domain. 
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